Neurocrine Biosciences, Inc. - Common Stock · Transaction Jun 17, 2025 · Filed Aug 13, 2025 · $1,001 to $15,000
XNAS · NBIX
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Neurocrine Biosciences Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$140.71
Follow $NBIX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NBIX by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredThu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET · NBIX
MethodologyNBIX
Neurocrine Biosciences Inc
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
70/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is NBIX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Neurocrine Biosciences Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
1996
Employees
3K
Country
US
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$140.71
Last session
Day high
$140.71
Last session
Day low
$140.71
Last session
Previous close
$140.71
52W high
$185.50
-24.15% from high
52W low
$123.10
28% of range
Market cap
$14.3B
P/E
21.99×
EPS
$6.40
Beta
0.10
Shares out
101.6M
Avg volume
1.2M
VWAP
$140.71
Last session
Price history computed in-house
1W
+1.67%
1M
-10.82%
3M
-19.25%
1Y
+2.90%
YTD
-0.79%
SMA 50 $156.27 · below
SMA 200 $147.33 · below
52W position 28%
NBIX overview
Related filings and maps
Public disclosures
Congress activity in NBIX
Official filing ↗
Neurocrine Biosciences, Inc. - Common Stock · Transaction Jun 11, 2025 · Filed Aug 13, 2025 · $1,001 to $15,000
Neurocrine biosciences, Inc. · Transaction Dec 21, 2020 · Filed Jan 11, 2021 · $1,001 to $15,000
Neurocrine biosciences, Inc. · Transaction Jul 21, 2020 · Filed Aug 19, 2020 · $1,001 to $15,000
Neurocrine biosciences, Inc. · Transaction Dec 13, 2018 · Filed Jan 4, 2019 · $1,001 to $15,000
Federal contracts
NBIX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NBIX in this window.
Lobbying spend
NBIX lobbying filings, year to date.
Registered lobbying filings matched to Neurocrine Biosciences Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NBIX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NBIX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.